Recent advances in therapy of sepsis: Focus on recombinant bactericidal/permeability-increasing protein (BPI)

BioDrugs

Volumn 9, Issue 6, 1998, Pages 435-442

  Elsbach, Peter ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID DERIVATIVE; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CALPROTECTIN; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE ANTIBODY; DEFENSIN; ENDOTOXIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LACTOFERRIN; LYSOZYME; PHOSPHOLIPASE; RECOMBINANT PROTEIN; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; COMPLEMENT ACTIVATION; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOMODULATION; INFECTION RESISTANCE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SEPSIS;

EID: 0031861263     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809060-00001     Document Type: Article

References (64)

1. Broekaert WF, Terras FR, Cammue BP, et al. Plant defensins: novel antimicrobial peptides as components of the host defense system. Plant Physiol 1995; 108 (4): 1353-8
2. Hoffman JA. Innate immunity of insects. Curr Opin Immunol 1995; 7 (1): 4-10
3. Rietschel ET, Brade H, Holst O, et al. Bacteriol endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 1996; 216: 39-81
4. Neumann D, Glauser MP. Pathogenesis of sepsis. Sci Am 1994 (Nov/Dec): 28-37
5. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326: 1153-7
6. Warren HS. Strategies for the treatment of sepsis. N Engl J Med 1997; 336 (13): 952-3
7. Vadas P, Browning J, Edelson J, et al. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 1993; 8 (1): 1-30
8. Vadas P, Pruzanski W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993; 39 (2): 160-7
9. Elsbach P, Weiss J. Oxygen-independent antimicrobial systems of phagocytes. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. 2nd ed. New York: Raven Press, 1992: 603-36
10. Levy O. Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol 1996; 56: 263-77
11. Ganz T, Lehrer RI. Antimicrobial peptides of leukocytes. Curr Opin Hematol 1997; 4 (1): 53-8
12. Ouellette AJ, Selsted ME. Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J 1996; 10 (11): 1280-9
13. Diamond G, Russell JP, Bevins CL. Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc Natl Acad Sci USA 1996; 93 (10): 5156-60
14. Weiss J. Leukocyte-derived antimicrobial proteins. Curr Opin Hematol 1994; 1: 78-84
15. Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994; 6 (4): 584-9
16. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374 (1): 1-5
17. Ooi CE, Weiss J, Levy O, et al. Isolation of two isoforms of a novel 15-kDa protein from rabbit polymorphonuclear leukocytes that modulate the antibacterial actions of other leukocyte proteins. J Biol Chem 1990; 265 (26): 15956-62
18. Levy O, Weiss J, Zarember K, et al. Antibacterial 15-kDa protein isoforms (p15s) are members of a novel family of leukocyte proteins. J Biol Chem 1993; 268 (8): 6058-63
19. Levy O, Ooi CE, Weiss J, et al. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest 1994; 94 (2): 672-82
20. Zarember K, Elsbach P, Shin-Kim K, et al. p15s (15-kD antimicrobial proteins) are stored in the secondary granules of rabbit granulocytes: implications for antibacterial synergy with the bactericidal/permeability-increasing protein in inflammatory fluids. Blood 1997; 89: 672-9
21. Weiss J, Inada M, Elsbach P, et al. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J Biol Chem 1994; 269 (42): 26331-7
22. Wright GC, Weiss J, Kim KS, et al. Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases. J Clin Invest 1990; 85 (6): 1925-35
23. Wright GW, Ooi CE, Weiss J, et al. Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate. J Biol Chem 1990; 265 (12): 6675-81
24. Elsbach P, Weiss J. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. Immunobiology 1993; 187 (3-5): 417-29
25. Elsbach P, Weiss J. Prospects for the use of recombinant BPI in the treatment of Gram-negative bacterial infections. Infect Agents Dis 1995; 4: 102-9
26. Larrick JW, Hirata M, Balint RF, et al. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995; 63 (4): 1291-7
27. Lehrer RI, Ganz T. Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Ann NY Acad Sci 1996; 797: 228-39
28. Weiss J, Elsbach P, Olsson I, et al. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978; 253 (8): 2664-72
29. Elsbach P, Weiss J, Franson RC, et al. Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem 1979; 254 (21): 11000-9
30. de Winter RJ, von der Mohlen MA, van Lieshout H, et al. Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm 1995; 45 (3): 193-206
31. von der Mohlen MA, Kimmings AN, Wedel NI, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 1995; 172 (1): 144-51
32. von der Mohlen MA, van Deventer SJ, Levi M, et al. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 1995; 85 (12): 3437-43
33. Gray PW, Flaggs G, Leong SR, et al. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem 1989; 264 (16): 9505-9
34. Gray PW, Corcorran AE, Eddy RL, et al. The genes for the lipopolysaccharide binding protein (LBP) and the bactericidal/permeability-increasing protein (BPI) are encoded in the same region of chromosome 20. Genomics 1993; 15: 188-90
35. Leong SR, Camerata T. Nucleotide sequence of the bovine bactericidal permeability increasing protein (BPI). Nucleic Acids Res 1990; 18: 3052
36. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 Angstrom resolution. Science 1497; 276: 1881-4
37. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem 1987; 262 (31): 14891-4
38. Ooi CE, Weiss J, Doerfler ME, et al. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med 1991; 174 (3): 649-55
39. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992; 90 (3): 1122-30
40. Weiss J, Olsson I. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 1987; 69 (2): 652-9
41. Weersink AJ, van Kessel KP, van den Tol ME, et al. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. J Immunol 1993; 150 (1): 253-63
42. Dentener MA, Francot GJ, Buurman WA. Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. J Infect Dis 1996; 173 (1): 252-5
43. Gazzano-Santoro H, Parent JB, Grinna L, et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992; 60 (11): 4754-61
44. Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli. J Clin Invest 1990; 86 (2): 631-41
45. Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest 1990; 85 (3): 853-60
46. Marra MN, Wilde CG, Griffith JE, et al. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990; 144 (2): 662-6
47. Marra MN, Wilde CG, Collins MS, et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148 (2): 532-7
48. Weinrauch Y, Foreman A, Shu C, et al. Extracellular Accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest 1995; 95: 1916-24
49. Iovine N, Elsbach P, Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci USA 1997; 94: 10973-8
50. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249 (4975): 1429-31
51. Ulevitch RJ, Dunn DL, Fink MP, et al. Endotoxin-related intracellular pathways: implications for therapeutic intervention. Shock 1996; 6 (1): 1-2
52. Gazzano-Santoro H, Meszaros K, Birr C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and Gram-negative bacteria. Infect Immun 1994; 62: 1185-91
53. Gazzano-Santoro H, Parent JB, Conlon PJ, et al. Characterization of the structural elements in lipid A required for binding of a recombinant fragment of bactericidal/ permeability-increasing protein rBPI23. Infect Immun 1995; 63: 2201-5
54. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 1994; 6 (1): 125-30
55. Dentener MA, Von Asmuth E, Francot GJ, et al. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J Immunol 1993; 151 (8): 4258-65
56. Tobias PS, Soldau K, Iovine N, et al. Lipopolysaccharide (LPS) binding proteins BPI and LBP form different complexes with LPS. J Biol Chem 1997; 272 (30): 18682-5
57. Katz SS, Chen K, Chen S, et al. Potent CD14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin. Infect Immun 1996; 64: 3592-600
58. Tobias PS, Soldau K, Gegner JA, et al. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 1995; 270 (18): 10482-8
59. Ammons WS, Kohn FR, Kung AHC. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of Gram-negative sepsis: role of bactericidal properties. J Infect Dis 1994; 170: 1473-82
60. Kung AH, Ammons WS, Lin Y, et al. Efficacy of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria. Prog Clin Biol Res 1994; 388: 255-63
61. Lin Y, Kohn FR, Kung AH, et al. Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia. Biochem Pharmacol 1994; 47 (9): 1553-9
62. Lin Y, Ammons WS, Leach WJ, et al. Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock 1994; 2 (5): 324-31
63. Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob Agents Chemother 1996; 40 (1): 65-9
64. Giroir BP, Quint PA, Barton P, et al. Evaluation in rBPI21 (recombinant amino terminal fragment in human bactericidal/permecability-increasing protein) in children with severe meningococcal disease. Lancet 1997; 350: 1439-43